ES2180527T3 - Agente para el tratamiento de enfermedades oseas que contienen el factor basico de crecimiento de los fibroblastos. - Google Patents

Agente para el tratamiento de enfermedades oseas que contienen el factor basico de crecimiento de los fibroblastos.

Info

Publication number
ES2180527T3
ES2180527T3 ES91121597T ES91121597T ES2180527T3 ES 2180527 T3 ES2180527 T3 ES 2180527T3 ES 91121597 T ES91121597 T ES 91121597T ES 91121597 T ES91121597 T ES 91121597T ES 2180527 T3 ES2180527 T3 ES 2180527T3
Authority
ES
Spain
Prior art keywords
treatment
agent
bone
oseas
fibroblasts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91121597T
Other languages
English (en)
Inventor
Keigo Hanada
Yoshiyuki Hiyama
Makoto Tamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaken Pharmaceutical Co Ltd
Original Assignee
Kaken Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd filed Critical Kaken Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2180527T3 publication Critical patent/ES2180527T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EL OBJETO DE ESTA INVENCION ES SUMINISTRAR UN AGENTE PARA EL TRATAMIENTO DE LA ENFERMEDAD DE HUESOS QUE PUEDE ACORTAR EL PERIODO DE CURACION DE DIVERSAS FRACTURAS, INCLUYENDO LA ACELERACION DE LA FORMACION DE HUESOS, QUE PUEDE MEJORAR LA RESISTENCIA DE HUESOS SOLDADOS Y QUE TAMBIEN PUEDE MEJORAR LA FORTALEZA DE HUESOS DEBILITADOS POR DIVERSAS ENFERMEDADES. EL AGENTE COMPRENDE UN FIBROBLASTO DE FACTOR DE CRECIMIENTO COMO INGREDIENTE EFECTIVO
ES91121597T 1990-12-19 1991-12-17 Agente para el tratamiento de enfermedades oseas que contienen el factor basico de crecimiento de los fibroblastos. Expired - Lifetime ES2180527T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP41916890 1990-12-19
JP03152517A JP3135138B2 (ja) 1990-12-19 1991-05-28 骨疾患治療剤

Publications (1)

Publication Number Publication Date
ES2180527T3 true ES2180527T3 (es) 2003-02-16

Family

ID=26481415

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91121597T Expired - Lifetime ES2180527T3 (es) 1990-12-19 1991-12-17 Agente para el tratamiento de enfermedades oseas que contienen el factor basico de crecimiento de los fibroblastos.

Country Status (5)

Country Link
EP (1) EP0493737B1 (es)
JP (1) JP3135138B2 (es)
AT (1) ATE220915T1 (es)
DE (1) DE69133074T2 (es)
ES (1) ES2180527T3 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027630A1 (fr) * 1993-05-31 1994-12-08 Kaken Pharmaceutical Co., Ltd. Preparation de gel a base de gelatine reticulee contenant un facteur de croissance de fibroblaste de base
WO1995005840A1 (fr) * 1993-08-25 1995-03-02 Kaken Pharmaceutical Co., Ltd. Remede contre les affections periodontiques
US6221854B1 (en) * 1996-03-05 2001-04-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
EP1218026B1 (en) 1999-09-30 2004-03-31 Kaken Pharmaceutical Co., Ltd. Preparation of a medicament to enhance healing of the sternum after sternotomy
AU2003244459A1 (en) * 2002-02-04 2003-09-02 Koken Co., Ltd. Preparations for treating bone fracture or bone loss or elevating bone density
US7820438B2 (en) 2002-06-18 2010-10-26 Eisai R&D Management Co., Ltd. Primary cultured adipocytes for gene therapy
CN108324928B (zh) * 2018-03-05 2020-09-08 哈尔滨医科大学 重组人成纤维细胞生长因子-5在促骨折愈合中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE66689B1 (en) * 1985-09-12 1996-01-24 Scios Nova Inc Recombinant fibroblast growth factors
AU638402B2 (en) * 1987-11-24 1993-07-01 Amgen, Inc. Analogs of fibroblast growth factor
GB8821795D0 (en) * 1988-09-16 1988-10-19 Erba Carlo Spa New derivatives of human/bovine basic fibroplast growth factor
CA2002210C (en) * 1988-11-04 2001-04-24 Philip J. Barr Expression and processing of authentic fgf's in yeast
FR2642086B1 (fr) * 1989-01-26 1992-09-04 Sanofi Sa Gene recombinant codant pour un facteur basique de croissance des fibroblastes et ledit facteur

Also Published As

Publication number Publication date
JPH05124975A (ja) 1993-05-21
EP0493737B1 (en) 2002-07-24
ATE220915T1 (de) 2002-08-15
EP0493737A3 (en) 1992-12-30
DE69133074T2 (de) 2002-12-12
JP3135138B2 (ja) 2001-02-13
EP0493737A1 (en) 1992-07-08
DE69133074D1 (de) 2002-08-29

Similar Documents

Publication Publication Date Title
DE69021133D1 (de) Intramedullar-Nagel mit selbstverriegelbarem Ende zur Behandlung von metadiaphysialen Brüchen langer Knochen.
GR1000392B (el) Σταθεροποιημενες συνθεσεις περιεχουσες επιδερμικο παραγοντα αναπτυξης.
DE69524152D1 (de) Sterile Gelzusammensetzung zur Wundbehandlung
ITFI910071V0 (it) Piastra per osso per la porzione distale dell'omero
ATE67094T1 (de) Knochenzement.
IT1211783B (it) E la prevenzione della osteoporosi composizione di fluoro e calcio a e simili affezioni ossee lento rilascio, per il trattamento
DE3560902D1 (en) Vitamin d3 derivatives
ITBO920277A0 (it) Endoprotesi per osteosintesi del femore prossimale
ES2180527T3 (es) Agente para el tratamiento de enfermedades oseas que contienen el factor basico de crecimiento de los fibroblastos.
ES2071303T3 (es) Compuestos homologados de vitamina d2 y los derivados hidroxilados en 1alfa correspondientes.
DE69010294T2 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
DE69033606T2 (de) Verfahren zur verbesserung der wundheilung und gewebeerneuerung
PT96585A (pt) Processo para prparacao de uma composicao microbiocida para tratamento de telhas de betao
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
BR9508185A (pt) Composto de tetraésteres de ácido piridinil-aminometilideno- bisfônico composição farmacêutica processo para fabricar uma composição farmacêutica e método para tratar doenças ósseas
ITVR910067A1 (it) Fissatore esterno assiale per la composizione di fratture ossee
ATE193450T1 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von knochenbrüchen
ATE78658T1 (de) Stabilisierte feste zusammensetzung.
DK0520372T3 (da) Inositol-phosphat-analoger som calciumantagonistiske stoffer
ATE45670T1 (de) Verwendung von difunktionellen acrylsaeure- und methacrylsaeureestern zur herstellung von haertbaren knochenzementen.
ES2078305T3 (es) 2-alquil-3-benzoilbenzofuranos utiles para el tratamiento de la arritmia cardiaca.
DE69108319T2 (de) Verfahren zur herstellung von vitamin-d2-verbindungen und ihrer 1-alpha hydrogenierten derivate.
ES291814Y (es) Protesis perfeccionada de osteosintesis para el tratamiento de las fracturas del femur
RU93052331A (ru) Способ удлинения трубчатой кости